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Abstract
Introduction: Tumors that express estrogen receptor alpha (ERa+) comprise 75% of breast cancers in women.
While treatments directed against this receptor have successfully lowered mortality rates, many primary tumors
initially or later exhibit resistance. The paucity of murine models of this “luminal” tumor subtype has hindered
studies of factors that promote their pathogenesis and modulate responsiveness to estrogen-directed therapeutics.
Since epidemiologic studies closely link prolactin and the development of ERa+ tumors in women, we examined
characteristics of the aggressive ERa+ and ERa- carcinomas which develop in response to mammary prolactin in a
murine transgenic model (neu-related lipocalin- prolactin (NRL-PRL)). To evaluate their relationship to clinical
tumors, we determined phenotypic relationships among these carcinomas, other murine models of breast cancer,
and features of luminal tumors in women.
Methods: We examined a panel of prolactin-induced tumors for characteristics relevant to clinical tumors:
histotype, ERa/progesterone receptor (PR) expression and estrogen responsiveness, Activating Protein 1 (AP-1)
components, and phosphorylation of signal transducer and activator of transcription 5 (Stat5), extracellular signal
regulated kinase (ERK) 1/2 and AKT. We compared levels of transcripts in the ERa-associated “luminal” signature
that defines this subtype of tumors in women and transcripts enriched in various mammary epithelial lineages to
other well-studied genetically modified murine models of breast cancer. Finally, we used microarray analyses to
compare prolactin-induced ERa+ and ERa- tumors, and examined responsiveness to estrogen and the anti-
estrogen, Faslodex, in vivo.
Results: Prolactin-induced carcinomas were markedly diverse with respect to histotype, ERa/PR expression, and
activated signaling cascades. They constituted a heterogeneous, but distinct group of murine mammary tumors,
with molecular features of the luminal subtype of human breast cancer. In contrast to morphologically normal and
hyperplastic structures in NRL-PRL females, carcinomas were insensitive to ERa-mediated signals. These tumors
were distinct from mouse mammary tumor virus (MMTV)-neu tumors, and contained elevated transcripts for factors
associated with luminal/alveolar expansion and differentiation, suggesting that they arose from physiologic targets
of prolactin. These features were shared by ERa+ and ERa- tumors, suggesting a common origin, although the
former exhibited transcript profiles reflecting greater differentiation.
Conclusions: Our studies demonstrate that prolactin can promote diverse carcinomas in mice, many of which
resemble luminal breast cancers, providing a novel experimental model to examine the pathogenesis, progression
and treatment responsiveness of this tumor subtype.
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The hormone, prolactin (PRL), is critical for the devel-
opment and functional differentiation of the mammary
gland [1]. Although its physiologic importance suggests
a role in breast carcinogenesis, such activity has been
controversial. However, accumulating evidence from a
variety of sources now supports a link between this hor-
mone and breast disease. Large prospective epidemiolo-
gic studies have correlated circulating levels of PRL with
an increased risk of particularly estrogen receptor posi-
tive (ERa+) invasive tumors [2]. Although the relation-
ship between circulating PRL and patient survival has
been examined only in smaller studies, higher levels
have been associated with tumor aggression, higher risk
of metastasis and poor long term survival (reviewed in
[2,3]). Moreover, the pituitary is not the only source of
PRL to the breast. PRL is also expressed within the
mammary gland, particularly in humans, permitting
autocrine/paracrine actions [4-6]. Recent studies have
begun to link genetic variations in the genes for PRL
and the prolactin receptor (PRLR) and breast cancer
[7-9]. Furthermore, in addition to PRL itself, human
growth hormone is also a potent agonist at the PRLR;
thus PRLR-transduced signals also may mediate some
signals of this other oncogenic hormone [10,11]. Finally,
many primary breast tumors, both ERa+a n dE R a-,
express the PRLR, pointing to its potential utility as a
therapeutic target and prognostic indicator [4,12,13].
Although epidemiological data support a role for PRL
in the development and progression of breast cancer,
relatively little is known about its contributions to this
disease. In order to investigate the pathogenic actions of
PRL, we have developed a transgenic mouse model
(NRL-PRL), which mimics the high mammary PRL
synthesis observed in women. In this model, the PRL-
and estrogen- insensitive NRL promoter drives expres-
sion of the rat PRL transgene in mammary epithelia,
exposing the gland to locally elevated PRL [14,15]. Non-
parous NRL-PRL females develop mammary pathology
that exhibits many features of human disease, including
early lesions (hyperplasias and intraepithelial neoplasias,
similar to ductal carcinoma in situ in women), and
eventually, ERa+a n dE R a- carcinomas. These tumors
are locally aggressive, and metastases to local lymph
nodes and lungs are occasionally observed [16]. The
d e v e l o p m e n to ft u m o r si nN R L - P R Lf e m a l e si sn o t
dependent on postpubertal ovarian steroids, but is accel-
erated by supplemental estrogen [17].
Expression of ERa has emerged as the foremost prog-
nostic and therapeutic indicator in primary clinical
breast tumors. However, ERa+ cancers are themselves
very diverse, and many are not susceptible to treatments
directed at this pathway. Indeed, 25% of women treated
with tamoxifen will succumb to breast cancer [18].
Large scale transcript profiling of clinical tumors has
begun to reveal the basis of ERa+ cancer diversity, as
well as that of other tumor subtypes defined by patholo-
gic markers (for review, [19]). ERa+t u m o r ss h a r et h e
“luminal” transcript signature, which includes the ERa
itself and several other genes linked to ERa expression,
as well as defining features such as luminal cytokeratins
[19,20]. Efforts to resolve luminal tumors into subtypes
that predict therapeutic sensitivity have demonstrated
elevated expression of proliferation-related genes in
patients at higher risk for relapse, which are useful clini-
cally [21-23]. However, these studies have not revealed
vulnerabilities that can be therapeutically targeted.
Mouse models have proven to be useful in elucidating
the origins of tumor subtypes, and have revealed com-
plex etiologies and relationships to mammary epithelial
lineages [24,25]. However, the paucity of murine models
of ERa+ tumors has hindered studies of the factors that
give rise to this prevalent tumor subtype and modulate
responsiveness to estrogen-directed therapeutics. In light
of the epidemiologic evidence linking PRL exposure to
the development of ERa+ cancers in women, we investi-
gated the phenotype of the mammary carcinomas that
develop in NRL-PRL females, with regard to features
defining clinical luminal tumors, including expression of
the “ERa-associated signature”, estrogen sensitivity, and
activated signaling pathways. Our studies demonstrate
that PRL can promote diverse tumor phenotypes, many
of which display molecular features of luminal breast
cancers, providing insight into the pathogenesis of this
cancer subtype.
Materials and methods
Reagents
5-bromo-2-deoxyuridine (BrdU) was obtained from
Sigma Chemical Co. (St. Louis, MO, USA), and 17b-
estradiol (E2) was purchased from Steraloids, Inc. (New-
port, RI, USA. The following antibodies were used for
immunohistochemical analyses: BrdU (MAS-250) from
Accurate Scientific (Westbury, NY, USA), proliferating
cell nuclear antigen (PCNA; PC 10) and progesterone
receptor (PR; A0098) from DAKO Cytomation (Carpin-
teria, CA, USA), c-Fos (SC-52) and estrogen receptor
alpha (ERa; SC-542) from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA), pERK 1/2 (Thr202/Tyr204;
9102), pAkt (S473; 3787), and c-Jun (9162) from Cell
Signaling Technology (Beverly, MA, USA), pStat5 (AX1)
from Advantex BioReagents, LLP (El Paso, TX, USA).
Mouse models
NRL-PRL mice (line 1655-8, TgN(Nrl-Prl)24EPS) were
generated and maintained in the FVB/N strain
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handled in accordance with the Guide for Care and Use
of Laboratory Animals in AAALAC-accredited facilities.
All procedures were approved by the University of Wis-
consin-Madison Animal Care and Use Committee.
p53
+/- heterozygotes [26] that were backcrossed more
than 10 generations into the FVB/N strain [27] were
used to generate p53
-/- donors. p53
-/- mammary epithe-
lial cells (MECs) were transplanted into FVB/N non-
transgenic female recipients, and the resulting tumors
harvested (manuscript in preparation, O’Leary and
Schuler). Mammary tumors from other genetically mod-
ified murine models (FVB/N) were generously provided
by Drs. Kim and Alexander (University of Wisconsin)
(MMTV-neu [28], and Drs. Green and Zi-Yao Liu
(NIH-NCI) (C3(1)-SV40 Tag tumors [29].
Histological examination of mammary tissue
For some studies, mice were injected with 200 mg/kg
body weight BrdU 1 h prior to sacrifice to label cells
undergoing DNA synthesis. For immunohistochemistry
(IHC), deparaffinized slides were exposed to 0.5% H2O2
in methanol to block endogenous peroxidase activity,
boiled for 15 minutes in 0.1 M citrate (pH = 6.0) or
0.1 M Tris (pH = 9.0) buffer for antigen retrieval, then
blocked, and incubated with the primary antibody over-
night (for individual antibodies, see Table S1 in Addi-
tional File 1). Slides were incubated with the secondary
antibody (BioGenex, San Ramon, CA, USA), followed by
peroxidase strepavidin and 3,3’ diaminobenzidine, and
counterstained with hematoxylin. Cells were labeled for
PCNA using Vector M.O.M. Basic kit (BMK-2202; Vec-
tor Laboratories, Burlingame, CA, USA). pStat 5 was
detected as described [30]. Serial sections of tumors
were examined for the different endpoints. For all IHC,
control sections were stained in parallel (negative con-
trols: omission of primary antibody, irrelevant antibody;
positive controls, appropriate for the antibody) as
described [14]. To determine labeling indices, 1,000
total cells in at least five randomly chosen microscopic
fields in divergent regions of each carcinoma were
counted by an investigator blind to the experimental
status.
Microarray experiments
I nap r e l i m i n a r ys t u d yt oc o m p a r et h et u m o r st h a t
develop in NRL-PRL to other mouse models of mam-
mary cancer, cDNA prepared from tumors was hybri-
dized to Agilent Mouse Oligo Microarrays (Agilent
Technologies Inc., Santa Clara, CA, USA) using total
RNA from equal numbers of C57Bl6/J and 129 male
and female pups as the reference sample, as previously
described [31]. Data were processed and hierarchical
clustering performed, as described [31].
To compare NRL-PRL tumors identified as ERa posi-
tive or negative by IHC, total RNA was purified using
RNeasy Midi Kits (Qiagen Inc., Valencia, CA, USA)
according to the manufacturer’s instructions. RNA
integrity was assessed using the RNA 6000 Nano Assay
and Agilent 2100 Bioanalyzer (Agilent Technologies
Inc.). Total RNA (10 μg) was reverse transcribed and
labeled with Cy5 using the Array 50 kit (Genisphere
Inc., Hatfield, PA, USA). MECs were isolated as
described [32] from 12-week-old nontransgenic nonpar-
ous FVB/N females, for common reference RNA. Refer-
ence RNA pooled from 15 mice was reverse transcribed
and labeled with Cy3. Tumor and reference samples
were co-hybridized overnight to Agilent Mouse cDNA
Microarrays (G4104A, 8,614 features), washed, and
scanned using Agilent’s dual-laser Microarray Scanner
(G2565BA) with Feature Extraction Software.
Genes with Cy3 and Cy5 intensity values higher than
100 were considered as expressed genes and were nor-
malized with lowess smoother followed by log base 2
transformation. Values that changed at least 1.5-fold in
either direction from the gene’sm e d i a nv a l u ew e r e
included in the class comparison. Genes differentially
expressed between ERa positive and negative classes
were determined with a significance threshold of uni-
variate tests at P < 0.01. Average linkage hierarchical
clustering on both the genes and samples was per-
formed using the gene list generated by class compari-
son. Analyses were performed using BRB ArrayTools
(version 3.6.0) developed by Dr. Richard Simon and
Amy Peng Lam (Biometric Research Branch, National
Cancer Institute). These data have been deposited in the
public database, ArrayExpress (E-MEXP-3013).
Real-time PCR
RNA from tumors and MECs was examined using quan-
titative real time PCR (qRT-PCR). cDNA was synthe-
s i z e df r o m1μg RNA using random hexamers
(Amersham Biosciences, Piscataway, NJ, USA) and
MMLV Reverse Transcriptase (Promega, Madison, WI,
USA), and qRT-PCR performed as described [17]. Nega-
tive (no cDNA) and positive controls were included
with each plate. Specific primer sequences are listed in
Table S2 in Additional File 1. Results were calculated
using the comparative CT method and normalized to
18S RNA, and data were analyzed for statistical signifi-
cance as described in the figure legends.
Tumor sensitivity to ovarian steroids
To examine the responsiveness of tumors to circulating
ovarian steroids, tumors were allowed to develop until
they reached 1.5 cm in diameter. About one-third of the
tumor mass was then removed, concomitant with ovx
or sham surgery, or ovx and subcutaneous treatment
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Research of America, Sarasota, FL, USA), which result
in plasma levels of 50 to 75 pg/ml [33]. Tumors were
measured twice weekly with calipers, and tumor volume
was calculated (the largest diameter x (the smallest
diameter)
2 × 0.4). Mice were humanely euthanized and
tissue collected when the tumors reached 1.5 cm in dia-
meter. Histological comparisons of the tumor biopsies
and end stage tumors were carried out as above.
For some experiments, 1 mm
3 NRL-PRL tumor frag-
ments were transplanted bilaterally into fourth inguinal
mammary glands of 12-week-old nontransgenic syn-
geneic FVB/N hosts. After the tumors grew to 0.75 cm
in diameter, recipient females were treated with ovx,
sham surgery, or sham surgery and weekly subcutaneous
injections of 5 mg Faslodex (ICI 182,780; AstraZeneca,
Wilmington, DE, USA). Tumors were measured and
collected as described above.
Statistical analyses
Statistical analyses were performed using Prism v.4.03
(GraphPad Software, Inc., San Diego, CA, USA). Differ-
ences were considered significant at P < 0.05.
Results and discussion
Locally elevated PRL leads to histologically diverse ERa
positive and ERa negative carcinomas
NRL-PRL nonparous females develop diverse invasive
mammary carcinomas with a long latency [14]. In order
to examine the breadth of tumor phenotypes promoted
by this prolonged PRL exposure, we examined a panel
of 39 of these tumors (mean latency +/- standard devia-
t i o n( S . D . ) ,1 8 . 2 + / - 3 . 6m o n t h s ) .T h em a j o r i t yw e r ea d e -
nocarcinomas of several histotypes; carcinosarcomas
constituted a minor population (Figure 1, Table 1).
These carcinomas varied widely in the proportion of
cells that expressed detectable ERa (0 to 79%). Nineteen
of the 39 tumors examined exhibited greater than 10%
ERa+ cells, a common clinically used threshold. The
majority did not express detectable progesterone recep-
tor (PR); only four tumors demonstrated PR immunos-
taining in more than 5% of the tumor cells. The
morphological heterogeneity suggests cooperation
between PRL and other oncogenic factors during the
long period of development of these tumors, similar to
that which may occur in women.
PRL-induced tumors display inverse Stat5 and AP-1
activation and elevated epithelial pAKT
PRL can activate multiple signaling cascades, which may
play distinct roles in its physiologic and pathogenic
actions in the mammary gland. In order to determine
the relationship of these signals to tumor characteristics,
we examined the activation of these pathways in the
panel of PRL-induced tumors by IHC. Signal transducer
and activator of transcription 5 (Stat5) is one of the best
characterized mediators of PRL activity, and is critical
for PRL-induced alveolar development during pregnancy
(for review, [1,34]). The tumors that developed in NRL-
PRL females contained variable proportions of cells with
nuclear pStat5 (range: 4.2 to 93.3%), which was not
related to ERa levels (Figure 2a, d, P > 0.05). Although
many glandular and solid tumors exhibited relatively
high proportions of cells containing nuclear pStat5, evi-
dence for activation of this pathway varied substantially
even among these histotypes. Many adenocarcinomas
demonstrated low nuclear pStat5, as did all of the poorly
differentiated carcinosarcomas (Table 1).
PRL can also initiate other signals, including several
MAP kinases, which are elevated in mammary lysates of
NRL-PRL females [17], and are particularly strongly
activated in some breast cancer cells lines [35]. PRL-
activated MAP kinases can increase synthesis and phos-
phorylation of multiple Activating Protein-1 (AP-1)
components, activating the AP-1 transcriptional enhan-
cer [36]. AP-1 target genes have been shown to enhance
cellular proliferation, survival, and invasion (for review,
[37-39]). Both c-Fos and c-Jun were variably expressed
in PRL-induced tumors (Figure 2b, c, e). Their expres-
sion was directly related to each other (data not shown,
P = 0.005, R = 0.83). Although adenosquamous carcino-
mas and carcinosarcomas had the highest levels of c-Fos
expression, a large subset of other histotypes also dis-
played significant staining (Table 1). Interestingly,
nuclear pStat 5 levels were negatively correlated with
both c-Fos (Figure 2e; P < 0.0001, R = -0.63) and c-Jun
(data not shown; P = 0.0058, R = -0.82). The inverse
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Figure 1 Mammary carcinomas that develop in NRL-PRL
females exhibit diverse histotypes, and express varying levels
of ERa. The proportion of cells containing immuno-detectable ERa
was quantitated as described in Materials and methods, and shown
related to tumor histotype. Each box represents a single tumor that
arose in a different NRL-PRL nonparous female. The dashed line
marks 10% ERa+ cells, a common clinically used threshold. (Tumor
histotypes: GL, glandular; Pap, papillar; Adsq, adenosquamous; C-S,
carcinosarcoma).
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tumors is consistent with our previous observation of
PRL signals to Stat5 and AP-1 in several breast cancer
cell lines [35].
The higher level of nuclear pStat5 in well-differen-
tiated PRL-induced carcinoma histotypes resembles the
association of pStat5 with features of more differentiated
clinical breast tumors (for review, [34]). In order to
examine the association of this pathway with molecular
phenotype in adenocarcinomas, we examined levels of
two transcripts associated with distinct mammary beha-
viors. The 5 PRL-induced adenocarcinomas with highest
nuclear pStat5 (70 to 93%) and low c-Fos had signifi-
cantly elevated transcripts for the proteinase inhibitor,
Expi, compared to those adenocarcinomas with lowest
pStat5 (4 to 10%, Figure 2f, P = 0.003). Expi expression
increases in early pregnancy [40], and is reduced in
PRLR
-/- mammary glands [41]. In contrast, the adeno-
carcinomas with lowest nuclear pStat5 contained
elevated mRNA for the metalloproteinase, Mmp9
(Figure 2g; P = 0.03), which in women is associated with
high tumor grade, metastasis, and reduced survival [42],
consistent with a more aggressive phenotype.
Elevation of phosphorylated extracellular signal regu-
lated kinases 1/2 (pERK1/2) is found in some clinical
tumors in women [43], and is increased in lysates of
NRL-PRL mammary glands [17]. The location of
pERK1/2 varied substantially among PRL-induced
tumors. The majority of the adenocarcinomas (68%)
demonstrated strong stromal staining with rare nuclear
staining in epithelial cells (Table 1, Figure 3a). In con-
trast, all of the carcinosarcomas in the panel displayed
both strong epithelial nuclear and cytoplasmic labeling
(Figure 3b, c). This histotype had significantly higher
levels of Vim (Figure 3h), but similar levels of Krt8 tran-
scripts compared to the adenocarcinomas (Figure 3i).
The spindle shaped cell morphology, loss of cell polarity,
and expression of Vim mRNA within these tumors sug-
gest the epithelial to mesenchymal transition (EMT, for
review, [44,45]). Significantly enhanced levels of Mmp9
transcripts were also detected in these tumors (Figure 3j).
The PI3K/AKT pathway also has been associated with
proliferation, survival, and EMT in human breast
tumors, as well as resistance to endocrine therapy
[46-48]. pAKT is also elevated in mammary glands of
NRL-PRL females [17]. The majority of the carcinomas
in this panel displayed strong pAKT labeling in both the
nuclei and cytoplasm of tumor epithelium (Table 1,
Figure 3d). Other tumors exhibited pAKT labeled cells
in both the stroma and epithelium, and a minority in
the stromal compartment alone (Figure 3e). Unlike
pERK1/2, pAKT expression was not correlated with a
specific histotype; carcinosarcomas demonstrated vari-
able expression levels of nuclear and cytoplasmic pAKT
(Figure 3f, g).
Together, these observations suggest that a broad
spectrum of signals may contribute to progression of
these carcinomas. Nuclear pStat5 is elevated in hyper-
plastic lesions in NRL-PRL glands [17], and early abla-
tion of Jak2 protects against PRL-induced tumors [49],
consistent with an important role for the Jak2-Stat5
p a t h w a yi nt h e i rg e n e s i s .H o w e v e r ,t h ed a t ap r e s e n t e d
here indicate that high pStat5 persists in only a minor
subset of established PRL-induced carcinomas, suggest-
ing that other signals drive progression of most of these
tumors. Elevated activities of AP-1 [50,51], AKT [52]
and MAP kinases, including ERK1/2 [43], have been
implicated in resistance to conventional chemotherapies
and anti-estrogens. PRL can activate these signals alone,
as well as potently coopera t ew i t hg r o w t hf a c t o r st o
enhance ERK1/2 and AKT activation in vitro and
in vivo [53-55]. In light of the variable levels of Prlr
Table 1 Characteristics of PRL-induced carcinomas by histotype
Glandular Solid Papillary Adenosquamous Carcinosarcoma
N1 0 3 1 0 3 4
ERa
1 10.0 ± 3.6
a 4.4 ± 2.9
b 21.1 ± 8.1 32.2 ± 10.2
a,b 8.2 ± 3.0
PR
1 1.5 ± 1.0 0.3 ± 0.2 13.8 ± 6.3 2.4 ± 1.4 0
pStat5
1 49.0 ± 8.13
a,b 66.6 ± 12.2
c,d,e 29.4 ± 18.7
c 23.9 ± 5.25
a,d 5.7 ± 1.9
b,e
c-Fos
1 18.3 ± 2.8
a 15.0 ± 2.5
b,c 17.6 ± 3.7
d 30.5 ± 4.4
a,b 25.2 ± 3.2
c,d
S phase
1 15.6 ± 1.7 15.0 ± 2.5 18.0 ± 2.0 14.7 ± 1.3 15.5 ± 2.2
Apoptotic
1 2.1 ± 0.3 3.6 ± 1.1 2.2 ± 0.3 1.9 ± 0.4 1.1 ± 0.2
pERK1/2
2 70% strong, 10% weak stromal;
30% epithelial
100% strong
stromal
90% strong stromal; 10%
epithelial
100% strong stromal 100% strong stromal
& epithelial
pAKT
2 50% epithelial; 20% stromal;
30% negative
67% epithelial; 33%
negative
70% epithelial; 10% stromal;
20% negative
33% epithelial & stromal;
67% negative
75% epithelial; 25%
negative
1% tumor epithelial cells that are positive, mean ± s.e.m (see Materials and methods). Same lower case letters indicate significant differences between histotypes
(P < 0.05; Students t-test).
2% of tumors of each histotype that displayed strong staining in different locations (stroma, epithelium, or both) as indicated.
ERa, estrogen receptor alpha; ERK, extracellular signal regulated kinase; PR, progesterone receptor; PRL, prolactin; Stat5, signal transducer and activator of
transcription 5.
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Figure 2 PRL-induced carcinomas demonstrate an inverse relationship between nuclear phosphorylated Stat 5 (pStat 5) and AP-1
proteins. (a) Nuclear pStat 5 staining in a glandular adenocarcinoma. (b) c-Fos expression in a glandular adenocarcinoma. (c) c-Jun staining in a
glandular adenocarcinoma. (d) The proportion of tumor cells that express ERa and nuclear pStat5 is not correlated. (e) Carcinomas exhibit a
significantly negative correlation between the proportion of cells that contain nuclear pStat 5 and c-Fos (P < 0.0001, R = -0.63). ERa, pStat 5, c-
Fos and c-Jun expression were evaluated and quantitated as described in Materials and Methods. Each box represents a single carcinoma that
arose in a different NRL-PRL nonparous female. Correlations were determined using Spearman’s non-parametric test. (f)Expi mRNA is significantly
increased in the adenocarcinomas expressing highest pStat5, compared to the lowest 5 (mean ± s.e.m., N =5 ;* ,P = 0.003). (g)Mmp9 mRNA is
significantly decreased in the adenocarcinomas expressing highest pStat5, compared to the lowest 5 (mean ± s.e.m., N =5 ;* ,P = 0.03). (f, g)
Transcript levels were measured using qRT-PCR as described in Materials and Methods. Original magnification: a, b, c, 400x.
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Figure 3 Adenocarcinomas exhibit activated ERK1/2 in stroma and AKT in epithelia; carcinosarcomas display strong epithelial pERK1/
2. (a) pERK1/2 localized in stromal cells of differentiated glandular adenocarcinomas. (b) Mammary carcinosarcomas demonstrated nuclear and
cytoplasmic staining for pERK1/2. (c) Carcinosarcoma from gland of NRL-PRL female (hematoxylin and eosin stain). (d) Glandular adenocarcinoma
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Carcinosarcomas had similar levels of keratin 8 transcripts compared to adenocarcinomas. (j)Mmp9 mRNA was significantly increased in
carcinosarcomas. Transcript levels were measured using qRT-PCR as described in Materials and Methods and represented as mean ± s.e.m.
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denote significant differences using ANOVA, followed by Newman-Keuls post test (P < 0.05). Original magnification: a, c, 200x; b, d, e, f, g, 400x.
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Page 7 of 15transcripts in these tumors (see below), it is clear that
PRL itself may play different roles in ongoing activation
of these pathways as they influence lesion progression,
tumor phenotype, and treatment sensitivity.
PRL-induced carcinomas share molecular features of
luminal tumors in women
To evaluate shared characteristics of PRL-induced carci-
nomas, in a preliminary study we examined the tran-
script profiles of six NRL-PRL carcinomas, including
three each of the most prevalent histotypes (glandular
and papillary), expressing variable levels of ERa (three
positive, three negative by IHC, not associated with his-
totype). Unsupervised hierarchical clustering based on
an intrinsic gene list developed for murine models [31]
showed that the NRL-PRL tumors formed a distinct
subgroup neighboring MMTV-neu tumors.
To compare the phenotype of NRL-PRL tumors more
closely to other well-studied genetically modified murine
models of breast cancer subtypes in the FVB/N strain
background, we compared levels of transcripts for ERa-
associated genes in the “luminal” signature [20] and
those enriched in various mammary epithelial lineages.
MMTV-neu tumors model clinical HER2+ tumors. Like
both human HER2+ tumors [25] and other murine
tumors that develop in response to MMTV-driven
oncogenes [31], MMTV-neu tumors display some char-
acteristics of the “luminal” tumor subtype in women.
Tumors in this extensively studied mouse model do not
express ERa or FoxA1, a transcription factor which co-
regulates many targets [56,57]. However, they do express
other ERa-associated genes, including Xbp1 and Gata 3
[58-60]. In contrast, tumors that develop in both C3(1)-
SV40 Tag females and transplanted p53
-/- models have
many features of “basal” tumors in women ([31,61],
O’Leary and Schuler, in prep).
Unlike the morphologically homogeneous MMTV-neu
tumors, levels of transcripts that mark luminal breast
cancers varied in NRL-PRL carcinomas, consistent with
the diverse tumors in this model (Figure 4, Figure S1 in
Additional File 1). In contrast to the majority of murine
models, PRL-induced adenocarcinomas expressed rela-
tively high levels of Esr1 mRNA, although as predicted
from the IHC, levels varied considerably (Figure 4a).
PRL-induced papillary carcinomas also contained com-
paratively high levels of the ERa-associated transcripts
in the luminal signature, including FoxA1 and Xbp1
(Figure 4b, c). Gata3 mRNA was readily detectably in
NRL-PRL tumors, but levels were lower than in
MMTV-neu tumors (Figure 4d). Although Gata3 speci-
fies ductal/alveolar cell fate and is markedly reduced in
Prlr
-/- glands [1], this transcription factor also maintains
luminal differentiation and is reduced in invasive breast
cancer [62], consistent with the less differentiated phe-
notype of the PRL-induced carcinomas.
In light of the luminal phenotype of many tumors
promoted by PRL, we examined levels of transcripts
associated with distinct mammary subpopulations and
differentiation processes [24,63]. PRL-induced tumors
displayed relatively high levels of Itga6 (encoding integ-
rin a6, CD49f) mRNA, a marker for stem cell and pro-
genitor populations (Figure 5a). They expressed
relatively low levels of transcripts for both Itgb1 (encod-
ing integrin b1, CD29), which marks stem cell and basal
but not luminal subpopulations (Figure 5b), and also
Itgb3 (encoding integrin b3, CD61), a marker for lumi-
nal progenitors (Figure 5c). In contrast, three of the four
NRL-PRL adenocarcinomas displayed relatively high
levels of CD44 (Figure 5d), an adhesion molecule asso-
ciated with stem cells and metastasis [64,65]. NRL-PRL
adenocarcinomas also contained elevated mRNA for
several transcription factors, which direct luminal/alveo-
lar cell expansion and differentiation, are co-expressed
with PRLR in many normal MECs, and are linked to
PRL in genetic models [1,66]. PRL-induced adenocarci-
nomas contained relatively high levels of mRNA for
Elf5, a PRL-induced factor that directs the alveolar line-
age [67], as well as CEBPb, a transcriptional regulator
which has been implicated in stem cell and luminal pro-
genitor repopulation [68] (Figure 5e, f). Consistent with
their roles in luminal cell commitment, individual
genetic ablations of Gata3, Elf5, C/EBPb and also Stat5
have been shown to alter the size of the MEC subpopu-
lation expressing integrin b3 (CD61+), which is enriched
in luminal precursors. However, the variable direction
and timing of the observed changes reflect their com-
plex actions at more than one stage of this process
[24,68,69]. Future studies will elucidate the effect of PRL
on mammary epithelial subpopulations and roles of
these transcriptional regulators in its actions, and illumi-
nate differences in cellular origin and/or pathways of
progression from MMTV-neu tumors and among the
different histotypes of PRL-induced carcinomas.
Transcripts for the cdk4/6 inhibitor, Cdkn2c
(p18
INK4c), were very low (Figure 5g). Genetic ablation
of this tumor suppressor induces well-differentiated
non-invasive luminal tumors in mouse models [70].
Similar results were observed for Cdkn2a (p16
INK4a, data
not shown). These results are consistent with the similar
mammary phenotypes of Prlr
-/- and Ccnd1
-/- mice [1],
and ability of PRL to increasec y c l i nD 1t r a n s c r i p t i o n
[71], and support a key role for cdk4/6 in PRL-induced
tumorigenesis.
PRL also may contribute to the tumor phenotype of
other models; some C3(1)-SV40 Tag as well as MMTV-
neu tumors contained appreciable Prlr mRNA (Figure 5h).
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Page 8 of 15The CD61+ progenitor population has recently been
shown to be the origin of basal tumors [72]; the size of
this MEC subpopulation is strongly modulated by Stat5.
These observations invite speculation on potential thera-
peutic or preventative approaches directed at PRL action
in multiple tumor types.
These marked differences in the molecular phenotype
of PRL-induced tumors compared to other genetically
modified mouse models of breast cancer suggest that
PRL acts on its physiological target cells to promote
diverse luminal-type tumors, but raises questions about
t h ei d e n t i t yo ft h e s ec e l l s ,t h er o l eo fm e d i a t o r sa s s o -
ciated with “normal” function in tumor progression, and
factors contributing to tumor heterogeneity. Develop-
ment of additional markers for the various mammary
epithelial subpopulations, and antibodies that recognize
the native conformation of the murine PRLR will assist
in determining the characteristics of the precursors of
luminal tumors, and identifying the target cells of PRL
in this process.
ERa expression is associated with distinct molecular
features, but does not confer estrogen responsiveness
In our preliminary studies comparing PRL-induced
tumors to other murine models of breast cancer, PRL-
induced ERa-a n dE R a+ tumors clustered together,
indicating shared features suggesting a common origin.
In order to determine characteristics of PRL-induced
tumors that are associated with differences in ERa pro-
tein expression, we compared transcript profiles from
four ERa+ and four ERa- adenocarcinomas (determined
by IHC) of divergent histotypes that did not segregate
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Figure 4 PRL-induced adenocarcinomas display molecular features of luminal clinical breast tumors.( a-d)R N Af r o mm a m m a r y
carcinomas that developed in NRL-PRL, MMTV-neu [28], C3(1)-SV40 Tag [29], and transplanted p53
-/- (O’Leary and Schuler, manuscript in
preparation) models was examined for levels of transcripts comprising the luminal signature [31] by qRT-PCR as described in the Materials and
Methods. PRL-induced papillary adenocarcinomas were of diverse ERa status by IHC. Each symbol denotes a distinct tumor. The horizontal bar
indicates the mean level for each model.
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Figure 5 NRL-PRL adenocarcinomas express markers distinct from other well-characterized models of breast cancer. RNA from the set
of mammary carcinomas in Figure 4 that developed in NRL-PRL, MMTV-neu [28], C3(1)-SV40 Tag [29], and transplanted p53
-/- (O’Leary and
Schuler, manuscript in preparation) models was examined for levels of transcripts implicated in mammary lineages by qRT-PCR as described in
the Materials and Methods. Each symbol denotes a distinct tumor. The horizontal bar indicates the mean level for each model.
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Page 10 of 15with ERa status (three papillary, two glandular, one ade-
nosquamous, two solid). Genes that were differentially
expressed among the classes were determined, and hier-
archical clustering analyses were performed by compar-
ing expression profiles both across the set of samples
and across the set of genes. As shown in Figure 6a,
ERa+a n dE R a- tumors clustered separately. Consistent
with the reports of ERa+ tumors in women, NRL-PRL
ERa+ tumors expressed higher levels of Gata-3 than
ERa- tumors, and markers of differentiation, such as the
milk proteins, b-casein and whey acidic protein, and
CD24a [20,73-75]. Levels of mRNA for the PRL trans-
gene and PRLR varied markedly among both ERa+a n d
ERa- carcinomas, suggesting that PRL activity itself was
not responsible for the differences observed (Figure S2
in Additional File 1).
Activity of the NRL-PRL promoter is not altered by
estrogen [15], enabling us to examine the role of this
steroid in the disease process. Proliferation of both mor-
phologically normal MECs and preneoplastic epithelial
hyperplasias in NRL-PRL females is very sensitive to
ovariectomy (ovx) and supplemental estrogen [17,54]. In
order to examine estrogen responsiveness in established
carcinomas, NRL-PRL females bearing primary mam-
mary adenocarcinomas were subjected to sham surgery
or ovx. At the time of surgery, a biopsy was removed
for examination of tumor histology, rate of proliferation,
and steroid hormone receptor expression. The growth
of the remaining tumors was monitored until they
reached 1.5 cm in diameter (15.3 ± 8.5 days; mean ±
s.d.), as described in the Materials and methods. Like
the tumors in Figure 1, histotypes in this experimental
panel were diverse, and ERa/PR expression varied
widely. They exhibited highly variable rates of growth
(Figure 6b); rates of proliferation of ERa- tumors prior
to the surgery tended to be higher than ERa+t u m o r s
(P = 0.07). However, ovx did not alter rates of prolifera-
tion of either ERa+o rE R a- tumor cells. Consistently,
ovx followed by administration of E2 failed to alter pro-
liferation of an independent set of primary tumors
(PCNA staining: 30.1% ± 12 vs 31.19% ± 7.9, mean ±
s.d., P > 0.05, N = 5).
Since primary PRL-induced tumors exhibit highly vari-
able histotype and ERa expression, and ovarian function
is likely to be faltering in the aged females, we employed
tumor transplantation to further investigate the role of
ERa-dependent signals in established tumors. We seri-
ally passaged NRL-PRL glandular adenocarcinoma frag-
ments that demonstrated high expression of both ERa
and PR (48% and 25% labeled cells, respectively) to
bilateral inguinal mammary glands of nonparous 12-
week-old syngeneic nontransgenic recipients. Although
the tumors that grew from these fragments (about eight
weeks per passage) retained the morphology and high
ERa expression of the original tumors, PR was no
longer detectable after passage (not shown), suggesting
that this process selects for more aggressive tumor cells.
After three passages, recipient females were treated with
ovx, sham surgery, or sham surgery and the ERa-selec-
tive antagonist, Faslodex. None of these treatments
altered rates of proliferation of the tumors, as measured
by BrdU incorporation (Figure 6c), indicating that rela-
tively well-differentiated ERa+ tumors display the estro-
gen independence observed in the more diverse group
of primary tumors.
These findings raise interesting questions regarding
the mechanism(s) whereby PRL interacts with ERa-
mediated signals in the development and progression of
ERa+ tumors. The striking estrogen independence of
established PRL-induced tumors shown herein contrasts
with the cooperation between PRL and estrogen in pro-
liferation of morphologically normal MECs and early
lesions [17,54], suggesting acquisition of estrogen insen-
sitivity. Many primary clinical ERa+ tumors acquire
resistance to estrogen-directed therapies and most dis-
play marked therapeutic insensitivity after metastasis. A
vast literature implicates many mechanisms, including
aberrations not only of ERa itself, but alterations in
other molecules and signaling pathways consistent with
heightened growth factor activity [76-78]. The ability of
PRL to potentiate growth factor signals [53-55,79] and
high activation of AKT in the tumors shown here are
consistent with a role in the latter mechanism. Clini-
cally, high circulating PRL has been associated with fail-
ure of ERa+ tumors to respond to tamoxifen and
aromatase inhibitors [80-82], and PRLR transcripts were
elevated with recurrence after tamoxifen treatment in
some studies [13,83]. The histological heterogeneity and
variable activation of signaling pathways of PRL-induced
tumors observed here suggest that multiple mechanisms
may lead to loss of estrogen sensitivity. Together, these
features suggest that the NRL-PRL model may provide
insight into the origin of the diversity of clinical ERa
tumors, and the characteristics of the tumor subpopula-
tion that resists therapy.
Conclusions
Despite the prevalence of ERa+ tumors clinically, very
few mouse models resemble this breast cancer subtype.
Our studies demonstrate that elevated local PRL can
promote diverse carcinomas, which display varying
levels of ERa/PR, nuclear pStat5, pERK1/2 and pAKT,
and AP-1 components. Transcript analysis demonstrates
that many of these carcinomas express the ERa-asso-
ciated transcript signature that defines this clinical
tumor subtype, and suggests that they arise from the
physiologic target cells of PRL. In contrast to morpholo-
gically normal structures and hyperplastic lesions,
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Figure 6 ERa+a n dE R a- carcinomas demonstrate distinct transcript profiles, and are insensitive to ovarian steroids. (a) Hierarchical
clustering of genes and tumor samples demonstrates differential expression between ERa+ (yellow) and ERa- (blue) adenocarcinomas at the
P < 0.01 significance level (N = 4 each). ERa+ was defined as ≥10% of the cells contained detectable ERa by IHC; ERa- contained <10%. Red
indicates high relative expression in ERa positive adenocarcinomas; green, low relative expression; black, no difference. Each column represents
an independent tumor, and each row is a gene. (b) Growth of PRL-induced tumors is not diminished by ovariectomy, regardless of ERa status.
Mammary carcinomas of distributed histotypes in NRL-PRL nonparous females were biopsied, and the mice subjected to sham surgery or
ovariectomy. Subsequent tumor growth was monitored until tumors reached 1.5 cm in diameter (15.3 ± 8.5 days; mean ± s.d.), and proliferation
determined by PCNA IHC as described in the Materials and Methods. Sham, N = 12; ovx ERa+, N = 10; ovx ERa-, N = 9. Treatment did not alter
the rate of growth (Student’s paired t-test, P > 0.05). (c) Treatment with the ER inhibitor and downregulator, Faslodex (ICI 182,780), does not
inhibit growth of ERa positive tumor fragments. Fragments of well-differentiated ERa+ tumors were transplanted into fat pads of nontransgenic
recipients and treated with ovariectomy, sham surgery, or Faslodex as described in Materials and Methods. Ovariectomized and Faslodex-treated
females had significantly reduced uterine weights (27 ± 5 mg, 30 ± 8 mg, mean ± s.d., respectively), compared to sham-treated females (83 ± 5
mg). Treatment did not alter the rate of proliferation (P > 0.05).
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Page 12 of 15established carcinomas are strikingly insensitive to estro-
gen, suggesting acquisition of independence. The role of
ongoing PRL signals in established tumors will require
additional investigation. Recent studies suggest that PRL
also can antagonize traditional chemotherapeutics in
breast cancer cells in vitro [84,85], which is supported
by small studies of PRL on therapeutic resistance in vivo
[86]. Together, our findings suggest that the NRL-PRL
mammary tumor model will be helpful to understand
the pathogenesis and heterogeneity of luminal tumors
and identify factors determining susceptibility to anti-
estrogen and traditional chemotherapies, to examine the
role of PRL in these responses, and to test novel thera-
peutic strategies, including combinatorial regimens
including therapies directed at PRL.
Additional material
Additional file 1: Supplementary tables and figures. Table S1:
Immunohistochemistry conditions. Description of retrieval methods,
blocking conditions and antibody dilutions used for each antigen
examined. Table S2: Primers employed for RT-PCR analyses. Sequences of
the primers used to quantify transcripts of interest. Figure S1: PRL-
induced carcinomas of different histotypes display variable levels of
transcripts for ERa-associated genes. Levels of mRNA for various
transcripts of interest in individual PRL-induced tumors of different
histotypes, determined by qRT-PCR. Figure S2: Levels of transgene and
Prlr transcripts are variable in NRL-PRL adenocarcinomas, and are not
associated with ERa status. Levels of mRNA for rPRL transgene and
cytokeratin 8 (Krt8), and PRL receptor in individual tumors, determined
by qRT-PCR.
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